Depicting Safety Profile of TAAR1 Agonist Ulotaront Relative to Reactions Anticipated for a Dopamine D2-Based Pharmacological Class in FAERS

por Hopkins, Seth C., Ogirala, Ajay, Worden, MaryAlice, Koblan, Kenneth S.
Publicado 2021

Depicting Risperidone Safety Profiles in Clinical Trials Across Different Diagnoses Using a Dopamine D(2)-Based Pharmacological Class Effect Query Defined by FAERS

por Hopkins, Seth C., Ogirala, Ajay, Zeni, Courtney, Worden, MaryAlice, Koblan, Kenneth S.
Publicado 2022

A randomized, single‐dose, crossover study of the effects of ulotaront on electrocardiogram intervals in subjects with schizophrenia

por Tsukada, Hironobu, Milanovic, Snezana M., Darpo, Borje, Xue, Hongqi, Xiong, Kuangnan, Tripp, Emily, Lennek, Lisa, Worden, MaryAlice, Hopkins, Seth C., Galluppi, Gerald R.
Publicado 2023

A Phase I, Open-Label, Fixed Sequence Study to Investigate the Effect of Cytochrome P450 2D6 Inhibition on the Pharmacokinetics of Ulotaront in Healthy Subjects

por Tsukada, Hironobu, Chen, Yu-Luan, Xiao, Guangqing, Lennek, Lisa, Milanovic, Snezana M., Worden, MaryAlice, Polhamus, Daniel G., Chiu, Yu-Yuan, Hopkins, Seth C., Galluppi, Gerald R.
Publicado 2023